Dr. Anthony Reder has a 30-year interest in multiple sclerosis.
He has coauthored over 150 papers, plus abstracts and presentations, on multiple sclerosis and animal models of MS. His primary research interests are in the interaction between the central nervous system (CNS) and the cellular immune system, and in how the brain and immune system are altered by the drugs we use to treat MS. Professor Reder has an active lab studying many facets of the immune disruption in MS, and also the mechanism of action of interferon-beta, the most widely-used treatment for MS. They have recently found that there is a defect in the interferon signaling pathway in lymphocytes from progressive forms of MS. This may be why some patients with progressive MS do not respond clinically to interferon therapy.
Dr. Reder and other faculty members at the University of Chicago have participated in the development of multiple new treatments for MS. These include the first biological therapy for MS, interferon-beta, plus other drugs including glatiramer (Copaxone), natalizumab (Tysabri), rituximab, ocrelizumab, estriol (the pregnancy hormone), and FTY720/fingolimod (Gilenya), plus drugs for pain in MS such as misoprostol. He has also evaluated IFN- patients 21 years after the original pivotal trial, the effects of statins and vitamin D on IFN efficacy, Current clinical trials include promising new drugs for neuromyelitis optica (NMO) and progressive MS.
He has trained a number of excellent MS fellows, funded by the US National MS Society. Prior fellows, Adil Javed, and as of Aug 1, Veronica Cipriani, are now on faculty at the U of Chicago. Dr. Javed defined a new variant of MS, CNS Sjögren’s disease, which requires different treatments than conventional MS.
Dr. Reder is also kind to puppies.
U of Chicago
Chicago
NMSS Sylvia Lawry Fellow - NeurorImmunology
1984
U of MN
Minneapolis
Internship and Residency - Neurology
1982
U of Michigan
Ann Arbor
BS - Psychology and Zoology
1974
U of Michigan
Ann Arbor
MD - All of medicine
1974
Novel biomarkers and interferon signature in secondary progressive multiple sclerosis.
Novel biomarkers and interferon signature in secondary progressive multiple sclerosis. J Neuroimmunol. 2024 Apr 15; 389:578328.
PMID: 38471284
Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives.
Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives. Neurol Ther. 2024 Apr; 13(2):283-322.
PMID: 38206453
Corrigendum: Adaptive and innate immune responses in multiple sclerosis with anti-CD20 therapy: gene expression and protein profiles.
Corrigendum: Adaptive and innate immune responses in multiple sclerosis with anti-CD20 therapy: gene expression and protein profiles. Front Neurol. 2023; 14:1245622.
PMID: 37614975
Demographics and baseline disease characteristics of Black and Hispanic patients with multiple sclerosis in the open-label, single-arm, multicenter, phase IV CHIMES trial.
Demographics and baseline disease characteristics of Black and Hispanic patients with multiple sclerosis in the open-label, single-arm, multicenter, phase IV CHIMES trial. Mult Scler Relat Disord. 2023 Aug; 76:104794.
PMID: 37356256
Understanding humoral immunity and multiple sclerosis severity in Black, and Latinx patients.
Understanding humoral immunity and multiple sclerosis severity in Black, and Latinx patients. Front Immunol. 2023; 14:1172993.
PMID: 37215103
Clostridium epsilon toxin is excessive in multiple sclerosis and provokes multifocal lesions in mouse models.
Clostridium epsilon toxin is excessive in multiple sclerosis and provokes multifocal lesions in mouse models. J Clin Invest. 2023 05 01; 133(9).
PMID: 37115699
Adaptive and innate immune responses in multiple sclerosis with anti-CD20 therapy: Gene expression and protein profiles.
Adaptive and innate immune responses in multiple sclerosis with anti-CD20 therapy: Gene expression and protein profiles. Front Neurol. 2023; 14:1158487.
PMID: 37168665
Effectiveness of rituximab versus oral immunosuppressive therapies in neuromyelitis optica spectrum disorder in a racially diverse cohort of subjects: A single-center retrospective study.
Effectiveness of rituximab versus oral immunosuppressive therapies in neuromyelitis optica spectrum disorder in a racially diverse cohort of subjects: A single-center retrospective study. Mult Scler Relat Disord. 2023 Jun; 74:104718.
PMID: 37086634
Prolonged Interferon-Stimulated Gene and Protein Signatures in Multiple Sclerosis Induced by PEGylated IFN-ß-1a Compared to Non-PEGylated IFN-ß-1a.
Prolonged Interferon-Stimulated Gene and Protein Signatures in Multiple Sclerosis Induced by PEGylated IFN-ß-1a Compared to Non-PEGylated IFN-ß-1a. J Interferon Cytokine Res. 2023 03; 43(3):108-120.
PMID: 36867172
Effectiveness of ocrelizumab on clinical and MRI outcome measures in multiple sclerosis across black and white cohorts: A single-center retrospective study.
Effectiveness of ocrelizumab on clinical and MRI outcome measures in multiple sclerosis across black and white cohorts: A single-center retrospective study. Mult Scler Relat Disord. 2023 Mar; 71:104523.
PMID: 36773543